Combining the GHRH antagonist peptide JMR-132 with docetaxel chemotherapy inhibited triple-negative breast cancer tumor growth by 71.6% in mice, significantly more than either treatment alone.
71.6% tumor inhibitionThe GHRH antagonist-docetaxel combination significantly outperformed either agent alone (46% and 50%) against triple-negative breast cancer in mice
What the researchers found
In MDA-MB-231 triple-negative breast cancer xenografts in nude mice:
- GHRH antagonist JMR-132 alone: 46% tumor growth inhibition
- Docetaxel alone: 50% tumor growth inhibition
- Combination: 71.6% tumor growth inhibition (p<0.001)
In vitro, both JMR-132 and docetaxel reduced cell viability dose-dependently, with the combination producing significantly greater inhibition than either agent alone. PCR array analysis of tumor tissue revealed that JMR-132 interacts with signal transduction pathways involved in proliferation, apoptosis, and angiogenesis, explaining its multi-faceted anti-tumor mechanism.
Why it matters
Triple-negative breast cancer affects about 15% of breast cancer patients and has the worst prognosis because it doesn't respond to hormonal or HER2-targeted therapies. Finding combination strategies that significantly improve on chemotherapy alone could meaningfully change outcomes for these patients.
How the study worked
GHRH receptor expression in MDA-MB-231 cells was confirmed by RT-PCR. In vitro cell viability assays tested JMR-132, docetaxel, and their combination. In vivo, nude mice bearing subcutaneous MDA-MB-231 xenografts received JMR-132 (10 µg/day s.c.) and/or docetaxel (10 mg/kg i.p. on days 1 and 5). A human cancer pathway array analyzing 84 genes was performed on tumor tissue to elucidate mechanism of action.
What this study cannot tell us
This is a preclinical study using a single TNBC cell line in immunocompromised mice. Human tumors are more heterogeneous and exist within a functional immune system. The dosing schedule was short-term, and long-term efficacy and toxicity were not assessed. Only one GHRH antagonist and one chemotherapy agent were tested.
How to read the evidence
This is a preclinical study using cell lines and mouse xenograft models. While the combination effect is statistically significant and mechanistically supported by gene expression data, results require validation in human clinical trials.
When this study was published
Published in 2013, this study contributed to the ongoing evaluation of peptide hormone antagonists for cancer treatment. GHRH antagonist research has continued to evolve since this publication.
The bigger picture
This study is part of Andrew Schally's extensive research program on peptide hormone antagonists for cancer. GHRH antagonists represent a peptide-based approach to cancer treatment that targets tumor growth signaling rather than directly killing cells, potentially complementing traditional chemotherapy with fewer overlapping side effects.
Questions still open
- Would this combination be effective in TNBC tumors with varying levels of GHRH receptor expression?
- Could GHRH antagonists enhance the effects of newer TNBC treatments like immunotherapy?
- What is the toxicity profile of long-term GHRH antagonist treatment in combination with chemotherapy?
Common questions
What is triple-negative breast cancer and why is it so hard to treat?
How does a GHRH antagonist fight cancer?
Read the original research
Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
Oncology reports, 30(1), 413-8
Citation
Seitz, S; Rick, F G; Schally, A V; Treszl, A; Hohla, F; Szalontay, L; Zarandi, M; Ortmann, O; Engel, J B; Buchholz, S. (2013). Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.. Oncology reports, 30(1), 413-8. https://doi.org/10.3892/or.2013.2435